BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adler CH, Beach TG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Patel A, Sue LI, Serrano G, Jacobson SA, Davis K, Belden CM, Dugger BN, Paciga SA, Winslow AR, Hirst WD, Hentz JG. GBA mutations in Parkinson disease: earlier death but similar neuropathological features. Eur J Neurol 2017;24:1363-8. [PMID: 28834018 DOI: 10.1111/ene.13395] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Furderer ML, Hertz E, Lopez GJ, Sidransky E. Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. Int J Mol Sci 2022;23:5842. [PMID: 35628652 DOI: 10.3390/ijms23105842] [Reference Citation Analysis]
2 Avisar H, Guardia-Laguarta C, Surface M, Papagiannakis N, Maniati M, Antonellou R, Papadimitriou D, Koros C, Athanassiadou A, Przedborski S, Lerner B, Stefanis L, Area-Gomez E, Alcalay RN. Lipid level alteration in human and cellular models of alpha synuclein mutations. NPJ Parkinsons Dis 2022;8:52. [PMID: 35468903 DOI: 10.1038/s41531-022-00313-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Pang SY, Lo RCN, Ho PW, Liu H, Chang EES, Leung C, Malki Y, Choi ZY, Wong WY, Kung MH, Ramsden DB, Ho S. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Transl Neurodegener 2022;11. [DOI: 10.1186/s40035-022-00281-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Caminiti SP, Carli G, Avenali M, Blandini F, Perani D. Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations. Mov Disord 2021. [PMID: 34596920 DOI: 10.1002/mds.28818] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
5 Li Q, Jing Y, Lun P, Liu X, Sun P. Association of gender and age at onset with glucocerebrosidase associated Parkinson's disease: a systematic review and meta-analysis. Neurol Sci 2021;42:2261-71. [PMID: 33837876 DOI: 10.1007/s10072-021-05230-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Navarro-Romero A, Montpeyó M, Martinez-Vicente M. The Emerging Role of the Lysosome in Parkinson's Disease. Cells 2020;9:E2399. [PMID: 33147750 DOI: 10.3390/cells9112399] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
7 Pingale T, Gupta GL. Current and emerging therapeutic targets for Parkinson's disease. Metab Brain Dis 2021;36:13-27. [PMID: 33090348 DOI: 10.1007/s11011-020-00636-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 von Linstow CU, Gan-Or Z, Brundin P. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. Transl Neurodegener 2020;9:39. [PMID: 33066808 DOI: 10.1186/s40035-020-00218-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
9 Olszewska DA, McCarthy A, Soto-Beasley AI, Walton RL, Magennis B, McLaughlin RL, Hardiman O, Ross OA, Lynch T. Association Between Glucocerebrosidase Mutations and Parkinson's Disease in Ireland. Front Neurol 2020;11:527. [PMID: 32714263 DOI: 10.3389/fneur.2020.00527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Ryan E, Seehra G, Sharma P, Sidransky E. GBA1-associated parkinsonism: new insights and therapeutic opportunities. Curr Opin Neurol 2019;32:589-96. [PMID: 31188151 DOI: 10.1097/WCO.0000000000000715] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
11 Xicoy H, Peñuelas N, Vila M, Laguna A. Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows. Cells 2019;8:E1317. [PMID: 31731485 DOI: 10.3390/cells8111317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
12 Fowler AJ, Moussa CE. Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease. CNS Drugs 2018;32:1-11. [PMID: 29492779 DOI: 10.1007/s40263-018-0497-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
13 Leija-Salazar M, Sedlazeck FJ, Toffoli M, Mullin S, Mokretar K, Athanasopoulou M, Donald A, Sharma R, Hughes D, Schapira AHV, Proukakis C. Evaluation of the detection of GBA missense mutations and other variants using the Oxford Nanopore MinION. Mol Genet Genomic Med 2019;7:e564. [PMID: 30637984 DOI: 10.1002/mgg3.564] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
14 Blandini F, Cilia R, Cerri S, Pezzoli G, Schapira AHV, Mullin S, Lanciego JL. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Mov Disord 2019;34:9-21. [PMID: 30589955 DOI: 10.1002/mds.27583] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 10.3] [Reference Citation Analysis]
15 Doppler K, Brockmann K, Sedghi A, Wurster I, Volkmann J, Oertel WH, Sommer C. Dermal Phospho-Alpha-Synuclein Deposition in Patients With Parkinson's Disease and Mutation of the Glucocerebrosidase Gene. Front Neurol 2018;9:1094. [PMID: 30619053 DOI: 10.3389/fneur.2018.01094] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
16 Atashrazm F, Hammond D, Perera G, Dobson-Stone C, Mueller N, Pickford R, Kim WS, Kwok JB, Lewis SJG, Halliday GM, Dzamko N. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. Sci Rep 2018;8:15446. [PMID: 30337601 DOI: 10.1038/s41598-018-33921-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 48] [Article Influence: 9.5] [Reference Citation Analysis]
17 Thaler A, Kozlovski T, Gurevich T, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. Mov Disord 2018;33:1656-60. [PMID: 30288804 DOI: 10.1002/mds.27490] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
18 Franco R, Sánchez-Arias JA, Navarro G, Lanciego JL. Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes. Front Neuroanat 2018;12:52. [PMID: 30002620 DOI: 10.3389/fnana.2018.00052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
19 Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.J Neural Transm (Vienna). 2018;125:615-650. [PMID: 29222591 DOI: 10.1007/s00702-017-1821-9] [Cited by in Crossref: 93] [Cited by in F6Publishing: 106] [Article Influence: 18.6] [Reference Citation Analysis]
20 [DOI: 10.1101/288068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]